...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial
【24h】

Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial

机译：乙酰胆碱酯酶抑制剂对阿尔茨海默氏病患者临床反应和脑血流变化的差异作用：一项为期12个月的随机和开放标签试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims: The present study evaluated the differences in treatment outcomes and brain perfusion changes among 3 types of acetylcholinesterase inhibitors (AchEIs, i.e. donepezil, rivastigmine, and galantamine). Methods: This was a prospective, longitudinal, randomized, open-label, 3-arm (donepezil, rivastigmine, or galantamine), parallel-group, 12-month clinical trial carried out in 55 patients with AD. Results: At 6 months, the results of the Mini-Mental State Examination (MMSE) and the Trail Making Test (TMT)-Part A showed an improvement versus baseline in the donepezil treatment group. All groups showed a significant increase in regional cerebral blood flow (rCBF), mainly in the frontal lobe. Significant rCBF reduction was observed in the temporal lobe and cingulate gyrus in all 3 groups. Conclusion: AchEI treatment prevents the progression of cognitive impairment and increases the relative rCBF in the frontal lobe.
机译：背景/目的：本研究评估了3种类型的乙酰胆碱酯酶抑制剂（AchEI，即多奈哌齐，卡巴拉汀和加兰他敏）在治疗效果和脑灌注变化方面的差异。方法：这是一项对55例AD患者进行的前瞻性，纵向，随机，开放标签，3组（多奈哌齐，卡巴拉汀或加兰他敏）平行组，为期12个月的临床试验。结果：在6个月时，多奈哌齐治疗组的最低精神状态检查（MMSE）和追踪试验（TMT）-A部分的结果显示改善。所有组均显示主要在额叶的局部脑血流量（rCBF）显着增加。在所有3组的颞叶和扣带回中均观察到rCBF显着降低。结论：AchEI治疗可预防认知障碍的进展并增加额叶的相对rCBF。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号